Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.68 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.67 |
| ▸ | THPO | P40225 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | NPY1R | P25929 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | NPY2R | P49146 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5962916 | 1.00 | ADORA3 (0.68) | ADORA3SLC29A1TP53TDP1LMNA | |
| SCHEMBL6699434 | 0.93 | ADORA3 (0.61) | ADORA3SLC29A1TP53TDP1LMNA | |
| SCHEMBL6699431 | 0.93 | ADORA3 (0.61) | ADORA3SLC29A1TP53TDP1LMNA | |
| SCHEMBL19224316 | 0.91 | ADORA3 (0.61) | ADORA3SLC29A1TP53TDP1LMNA | |
| SCHEMBL3634268 | 0.88 | LMNA (0.68) | ADORA3SLC29A1TP53TDP1LMNA | |
| SCHEMBL9565154 | 0.88 | LMNA (0.68) | ADORA3SLC29A1TP53TDP1LMNA | |
| SCHEMBL15455755 | 0.87 | P2RY12 (0.58) | ADORA3SLC29A1TP53TDP1LMNA | |
| SCHEMBL28758971 | 0.86 | ADORA2A (0.65) | ADORA3SLC29A1LMNATSHRNFKB1 | |
| SCHEMBL24920112 | 0.85 | ADORA2A (0.67) | ADORA3SLC29A1TP53LMNATSHR | |
| SCHEMBL30208521 | 0.85 | ADORA2A (0.67) | ADORA3SLC29A1TP53LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364121-A1 | NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY | Atea Pharmaceuticals, Inc. (US) | 2023-11-16 | — | — | US | disclosed |
| EP-4225282-A1 | NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY | ATEA Pharmaceuticals, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076903-A1 | NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY | Atea Pharmaceuticals, Inc. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20060223990-A1 | Synthesis, deprotection, analysis & purification of RNA & ribozymes | SIRNA THERAPEUTICS, INC. | 2006-10-05 | — | — | US | disclosed |
| US-7041817-B2 | Synthesis, deprotection, analysis and purification of RNA and ribozymes | SIRNA THERAPEUTICS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-20040033568-A9 | Method and reagent for treatment of diseases caused by expression of the c-myc gene | RIBOZYME PHARMACEUTICALS, INC. | 2004-02-19 | — | — | US | disclosed |
| US-6649751-B2 | Reacting biopolymers with alkylamines and ammonium hydroxide, heating and eluting through columns having ion exchange resins, then recovering the polynuleotides; solid phase synthesis | SIRNA THERAPEUTICS, INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030186923-A1 | Method and reagent for inhibiting P-glycoprotein (mdr-1 gene) | RIBOZYME PHARMACEUTICALS, INC. | 2003-10-02 | — | — | US | disclosed |
| US-20030166917-A1 | SYNTHESIS, DEPROTECTION, ANALYSIS AND PURIFICATION OF RNA AND RIBOZYMES | SIRNA THERAPEUTICS, INC. | 2003-09-04 | — | — | US | disclosed |
| US-20030162264-A1 | Method and reagent for treatment of diseases caused by expression of the c-myc gene | RIBOZYME PHARMACEUTICALS, INC. | 2003-08-28 | — | — | US | disclosed |
| WO-1995019429-A2 | METHOD AND REAGENT FOR INHIBITING HEPATITIS C VIRUS REPLICATION | RIBOZYME PHARMACEUTICALS, INC. (US) | 1995-07-20 | — | — | WO | disclosed |
| EP-0654077-A1 | METHOD AND REAGENT FOR TREATMENT OF ANIMAL DISEASES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1995-05-24 | — | — | EP | disclosed |
| WO-1995013380-A2 | METHOD AND REAGENT FOR TREATMENT OF ARTHRITIC CONDITIONS | RIBOZYME PHARMACEUTICALS, INC. (US) | 1995-05-18 | — | — | WO | disclosed |
| WO-1995011910-A1 | 2'-AMIDO AND 2'-PEPTIDO MODIFIED OLIGONUCLEOTIDES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1995-05-04 | — | — | WO | disclosed |
| EP-0642589-A1 | METHOD AND REAGENT FOR INHIBITING VIRAL REPLICATION | RIBOZYME PHARMACEUTICALS, INC. (US) | 1995-03-15 | — | — | EP | disclosed |
| EP-0641212-A1 | METHOD AND REAGENT FOR INHIBITING CANCER DEVELOPMENT | RIBOZYME PHARMACEUTICALS, INC. (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1995004818-A1 | METHOD AND REAGENT FOR INHIBITING HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | RIBOZYME PHARMACEUTICALS, INC. (US) | 1995-02-16 | — | — | WO | disclosed |
| WO-1994002595-A1 | METHOD AND REAGENT FOR TREATMENT OF ANIMAL DISEASES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1994-02-03 | — | — | WO | disclosed |
| WO-1993023057-A1 | METHOD AND REAGENT FOR INHIBITING CANCER DEVELOPMENT | RIBOZYME PHARMACEUTICALS, INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| WO-1993023569-A1 | METHOD AND REAGENT FOR INHIBITING VIRAL REPLICATION | RIBOZYME PHARMACEUTICALS, INC. (US) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364121-A1 | NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY | NSUN2, ACE2, PNP | ADORA3 2864/4885SLC29A1 566/4885TP53 680/4885 |
| US-20040033568-A9 | Method and reagent for treatment of diseases caused by expression of the c-myc gene | MYC, MYCBP, MYCBP2 | ADORA3 4526/4885SLC29A1 3998/4885TP53 66/4885 |
| US-20030162264-A1 | Method and reagent for treatment of diseases caused by expression of the c-myc gene | MYC, MYCBP, MYCBP2 | ADORA3 4526/4885SLC29A1 3998/4885TP53 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.